SLC22A17 and central nervous system cancer: Previous studies demonstrated that the aberrant expression of SLC22A17 is strictly associated with poor clinical outcomes in patients with endometrial carcinoma, glioma, and hepatocellular carcinoma (HCC) [63–65].